Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ93MR)

This product GTTS-WQ93MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ93MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12547MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ11998MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ13148MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ4607MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ14172MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ6916MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ9327MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ4551MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW